Ferric carboxymaltose


Ferric carboxymaltose

Drug updated on 4/24/2024

Dosage FormInjection (intravenous; 50 mg/mL, 100 mg/2 mL, 750 mg/15 mL, 1000 mg/20 mL)
Drug ClassIron replacement products
Ongoing and
Completed Studies


  • Indicated for the treatment of iron deficiency anemia (IDA) in adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron
  • Indicated for the treatment of iron deficiency anemia (IDA) in adult patients who have non-dialysis dependent chronic kidney disease.
  • Indicated for the treatment of iron deficiency anemia (IDA) in iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity.

This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Ferric carboxymaltose (Injectafer) is approved for the treatment of iron deficiency anemia in various groups. These include adults and pediatric patients over 1 year old who have not responded well or cannot tolerate oral iron, adult patients with non-dialysis-dependent chronic kidney disease, and those with heart failure.
  • Two systematic reviews/meta-analyses focused on the comparison of ferric carboxymaltose's efficacy and safety to other treatments, such as iron sucrose, among obstetric/gynecologic patients, and in the treatment of perioperative 3. In one study involving 910 obstetric/gynecologic patients across nine randomized controlled trials, ferric carboxymaltose led to significantly higher post-treatment serum hemoglobin levels compared with iron sucrose, with a mean difference of 0.67 g/dL favoring Injectafer.
  • Additionally, ferric carboxymaltose was associated with a lower incidence of adverse events compared to iron sucrose in these patient cohorts; no serious adverse events were reported, indicating a favorable safety profile for Injectafer within this group.
  • Another review on the treatment of perioperative anemia showed that preoperative administration of ferric carboxymaltose improved hematological parameters more effectively than comparators like placebo or standard care. It also potentially reduced transfusion rates and lengthened hospital stays among patients undergoing elective surgery and suffering from perioperative anemia.
  • Subgroup analyses suggest that findings are consistent across different types of surgeries (such as colorectal, gastric, and orthopedic), enhancing understanding of its applicability in diverse clinical scenarios. This underscores the need for further research, especially concerning long-term effects related specifically to its use in perioperative care settings.

Product Monograph / Prescribing Information

Document TitleYearSource
Injectafer (ferric carboxymaltose) Prescribing Information.2023American Regent, Inc., Shirley, NY

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy and safety of intravenous iron repletion in patients with heart failure: a systematic review and meta-analysis.2023Clinical Research in Cardiology
A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose. 2023International Journal of Clinical Pharmacy
Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis.2023European Heart Journal
Hypophosphataemia risk associated with ferric carboxymaltose in heart failure: a pooled analysis of clinical trials. 2023European Journal of Heart Failure
A systematic review, meta-analysis, and indirect comparison of blindly adjudicated cardiovascular event incidence with Ferric Derisomaltose, Ferric Carboxymaltose, and Iron Sucrose.2022Advances in Therapy
Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for iron deficiency anemia in obstetric and gynecologic patients; a systematic review and meta-analysis.2021Medicine
Ferric Carboxymaltose for anemic perioperative populations: a systematic literature review of randomized controlled trials. 2021Journal of Blood Medicine
Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis.2021British Journal of Clinical Pharmacology
Ferric carboxymaltose for anemic perioperative populations: a systematic literature review of randomized controlled trials.2021Journal of Blood Medicine

Clinical Practice Guidelines